Gaudium IVF IPO
Gaudium IVF IPO — date, price band, GMP & allotment 2026
Gaudium IVF & Women Health Limited IPO opens on 20 February 2026 and closes on 24 February, with allotment finalised by 25 February and listing tentatively on 27 February on BSE and NSE. Incorporated in March 2015, the company was founded by Dr Manika Khanna to provide advanced fertility treatments across India using a hub-and-spoke model. It specialises in IVF, ICSI, IUI, ovulation induction, gynaecological care for PCOD/PCOS, and high-risk pregnancy management.
Stock price
Gaudium IVF is listed — here is the live share price.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
Timetable
Key dates from opening to listing. Today is 11 September.
- Open 20 Feb 2026
- Close 24 Feb 2026
- Allotment 25 Feb 2026
- Refund/credit 26 Feb 2026
- Listing 27 Feb 2026
Issue summary
The terms of the offer, as filed.
| IPO Dates | 20 to 24 Feb, 2026 |
|---|---|
| Price Band | ₹75 – ₹79 |
| Face Value | ₹5 |
| Lot Size | 189 Shares |
| Issue Size | ₹165 Cr |
| Sale Type | Fresh capital cum OFS |
| Listing On | NSE & BSE |
| Registrar | Bigshare Services Private Limited |
| Min Investment | ₹ 14,931 |
Share of the offer set aside for each investor category, as stated in the offer document.
What will it cost me?
Bidding is in multiples of 189 shares at the ₹79 cut-off. Drag to size your application.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 189 | ₹14,931 |
| Retail (max) | 13 | 2,457 | ₹1,94,103 |
| S-HNI (min) | 14 | 2,646 | ₹2,09,034 |
| S-HNI (max) | 66 | 12,474 | ₹9,85,446 |
| B-HNI (min) | 67 | 12,663 | ₹10,00,377 |
Three years of numbers
All figures in ₹ crore, as reported in the Gaudium IVF offer document.
| Metric | 30 sep 2025 | 31 Mar 25 | 31 Mar 24 |
|---|---|---|---|
| Revenue | 49.75 | 70.96 | 48.15 |
| EBITDA | 18.95 | 28.63 | 19.27 |
| Net Profit | 12.51 | 19.13 | 10.32 |
| Debt | 22.51 | 15.60 | 26.00 |
| Assets | 106.62 | 88.51 | 51.01 |
See how this IPO compares — view listing performance of all mainboard IPOs.
Valuation & key ratios
Ratios are for the latest full financial year reported in the Gaudium IVF RHP. EPS and P/E are post-issue — the table below carries the pre-issue comparison.
Gaudium IVF IPO Valuation
How the issue prices the company before and after the fresh shares are created.
| Valuation Metric | Post-Issue |
|---|---|
| EPS (₹) | ₹3.12 |
| P/E Ratio (x) | 22.99 |
| Market Cap at Offer Price (₹ Cr) | ₹316.76 |
Pre-issue figures use the shareholding reported in the RHP; post-issue figures use the shareholding once the fresh issue has created new shares. The two differ because of that dilution and because post-issue earnings per share are often annualised, so the change can run in either direction. Market capitalisation is calculated at the ₹79 offer price. Compare the post-issue P/E against listed peers before deciding — a premium there is growth you are paying for in advance.
Where the money goes
₹70.00 Cr of the issue is earmarked to named objects.
Gaudium IVF IPO Anchor Investors
4 anchor investors across 4 fund houses committed ₹49.50 Cr a day before the issue opened.
| Anchor Investor | Fund House | Shares | Amount (₹ Cr) | % of Anchor Book |
|---|---|---|---|---|
| Meru Investment Fund Pcc-Cell 1 | Meru Investment | 2,151,330 | 17.00 | 34.33% |
| Sanshi Fund-I | Sanshi | 1,582,308 | 12.50 | 25.25% |
| Hornbill Orchid India Fund | Hornbill Orchid | 1,266,300 | 10.00 | 20.21% |
| Carnelian India Multi Strategy Fund | Carnelian | 1,265,922 | 10.00 | 20.20% |
| Total anchor allocation | 49.50 | |||
Anchor investors bid a day before the issue opens and are locked in after allotment, so a book weighted towards domestic mutual funds is generally read as a stronger signal than one filled by short-horizon funds. Browse every anchor investor scheme or fund house we track.
About the company
The company offers a comprehensive suite of services including IVF (in-vitro fertilisation), IUI (intrauterine insemination), ICSI, egg freezing, fertility preservation, and advanced diagnostic solutions. Its business model is primarily clinic-based, generating revenue through treatment cycles, consultations, and specialised procedures. Gaudium IVF focuses on personalised treatment plans, leveraging technology and experienced medical professionals to improve outcomes. By maintaining quality standards and expanding through new centres and partnerships, the company aims to strengthen its presence in India’s growing fertility services market while ensuring consistent patient care and long-term trust.
Interested in this IPO? Check the live subscription status or browse all upcoming mainboard IPOs.
011-4885 8585
The bankers & the filings
Who is running the book, and the documents this page is built from.
Gaudium IVF IPO Documents
Read the filings this page is built from.
Lead Manager Track Record
How the book-running lead managers on this issue have priced their past IPOs, measured on listing day.
Sarthi Capital Advisors Pvt.Ltd.
2 issues handled1 of their issues has listed so far, and 0 opened above the issue price (average -21.2%). That is too small a sample to read as a hit rate.
Listing gain compares the listing-day opening price with the issue price, using the IPOs on IPO Guru that this lead manager has taken to market. A strong record reflects how the banker has priced past issues — it is not a forecast for this one. See every issue they have handled on the lead managers page.
Company contact
Frequently asked
What is the GMP of Gaudium IVF?
The current Grey Market Premium is ₹-5, or -6% over the issue price.
What is the Gaudium IVF IPO price band?
₹75 to ₹79, on a face value of ₹5.
When is the allotment?
The basis of allotment is 25 February 2026, with listing on 27 February 2026.
How do I check allotment status?
On the IPO Guru allotment page or on the registrar's site — Bigshare Services Private Limited.
Every number here traces back to a filing.
IPO Guru tracks GMP, subscription and allotment for every Mainboard and SME issue. Every number on this page is sourced from the RHP, BSE & NSE.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.
